The aim of this review is to discuss the biological pathways potentially involved in the action of SGLT2i and GLP1-RA which may explain their effective role in the treatment of HF (Figure 1), as well as the potential implications of the use of these agents, also in combination therapies with neurohormonal agents, in clinical practice. This evidence concerns the gene GLP1R and hydrops fetalis.